King Pharmaceuticals submits proposal for acquisition of Alpharma
King’s all-cash proposal is said to represent a 37% premium over the closing price of Alpharma common stock on August 21, 2008, the last trading day prior to
Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.